Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides

Archives of Dermatology

Volumn 135, Issue 1, 1999, Pages 26-32

  Kim, Youn H ^a,b   Chow, Steve ^a   Varghese, Anna ^a   Hoppe, Richard T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG COST; ELECTRON BEAM; FEMALE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; SKIN LYMPHOMA; SURVIVAL RATE; T CELL LYMPHOMA; TOPICAL DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MECHLORETHAMINE; MIDDLE AGED; MYCOSIS FUNGOIDES; RADIOTHERAPY, HIGH-ENERGY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032927761     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.135.1.26     Document Type: Article

References (17)

1. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer. 1990;14:295-371.
2. Kim Y, Hoppe R. Cutaneous T-cell lymphomas. In: Magrath I. ed. The Non-Hodgkin's Lymphomas. 2nd ed. London. England: Edward Arnold & Oxford University Press Inc; 1997:907-926.
3. Kim Y, Hoppe R. Mycosis fungoides and the Sézary syndrome. In: Holland J. ed. Cancer Medicine. 4th ed. Baltimore, Md: Williams & Wilkins; 1997:2797-2808.
4. Green S, Byar D, Lamberg S. Prognostic variables in mycosis fungoides. Cancer. 1981;47:2671-2677.
5. Lamberg S, Green S, Byar D, Block J, Vonderheid E. Clinical staging 7or cutaneous T-cell lymphoma. Ann Intern Med. 1984;100:187-192.
6. Sausville E, Eddy J, Makuch R, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: definition of three distinctive prognostic groups. Ann Intern Med. 7988;109:372-382.
7. Weinstock M, Horm J. Population-based estimate of survival and determinants of prognosis in patients with mycosis fungoides. Cancer. 1988;62:1658-1661.
8. Kim Y, Jensen R, Watanabe G, Vargbese A, Hoppe R. Clinical stage IA (limited patch and plaque) mycosis fungoides: a long-term outcome analysis. Arch Dermatol. 1996;132:1309-1313.
9. Kim Y, Bishop K, Varghese A, Hoppe R. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol. 1995;131:1003-1008.
10. Bunn P. Larnberg S. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep. 1979;63:725-728.
11. Hoppe R, Abel E, Deneau D, Price N. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987;5:1796-1803.
12. Hoppe R. Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol. 1991;25:80-89.
13. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:475-480.
14. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-233.
15. Cox D, Snell E. Analysis of Binary Data. New York, NY: Chapman & Hall: 1989.
16. US Dept of Health and Human Services PHS. Centers for Disease Control. National Center for Health Statistics. US Decennial Life Tables. 1979 Through 1981. Hyattsville. Md: US Dept of Health and Human Services: 1988;1:12-15. Public Health Service publication 88-1150-2.
17. Quiros P, Jones G, Kacinski B, Braverman I, Heald P, Edelson R, Wilson L. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38:1027-1035.